Epistaxis in anticoagulated patients: Fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon

Abstract

Objectives

Treatment of epistaxis in patients on anticoagulants is challenging and associated with higher admission rates and longer hospital stays compared to patients without anticoagulation. However, there is little information about epistaxis in patients taking new direct oral anticoagulants such as rivaroxaban compared to patients on traditional vitamin-K antagonists such as phenprocoumon.

Design

Retrospective cohort study.

Setting

The study was conducted at the emergency department of the University Hospital Inselspital, Bern, Switzerland.

Participants

All admissions to the emergency department of the University Hospital Inselspital, Bern, Switzerland from July 1st 2012 to June 30th 2016 with non-traumatic epistaxis on anticoagulant therapy with phenprocoumon or rivaroxaban were included.

Main outcome measures

We compared clinical outcome parameters (admission rates, length of hospital stay and mortality) for both anticoagulant groups.

Results

We included 440 patients with epistaxis, 123 (28%) on rivaroxaban and 317 (72%) on phenprocoumon. Fewer hospital admissions and shorter hospital stays were found in patients under rivaroxaban (12 (10.4%) vs. 57 (18.0%) patients, p=0.033; 0.7±2.2 vs. 1.5±3.7 days, p=0.011) compared to phenprocoumon. Anterior epistaxis was more common in the rivaroxaban group in contrast to posterior epistaxis in patients on phenprocoumon (74 (60.2%) vs. 139 (43.8%) patients, p=0.002; 7 (5.7%) vs. 39 (12.3%) patients, p=0.042).

Conclusions

Our data suggests that epistaxis on direct oral anticoagulation with rivaroxaban is associated with shorter hospital stays and fewer hospital admissions than epistaxis on vitamin-K antagonist phenprocoumon.

This article is protected by copyright. All rights reserved.

http://ift.tt/2rnbErA